ClinicalTrials.gg
CompletedNCT02690220Updated Oct 23, 2019

Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh

An interventional study of TiLOOP® PRO Plus A in Cystocele and Uterine Prolapse, sponsored by pfm medical gmbh. Completed at 5 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.

Sponsored by pfm medical gmbh · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to determine the influence of anterior pelvic prolapse reconstruction with a titanized polypropylene mesh on patients quality of life.

Read the detailed description

This multicentre, non-randomized, observational clinical investigation will be performed to obtain usability and postmarket information on the TiLOOP® pelvic floor reconstruction meshes and in particular to obtain the improvement of patients' quality of life.

It is expected that the patient's quality of life is meliorated after implantation of a TiLOOP® PRO A mesh. To verify this, it will be shown that by means of a validated questionnaire the subjective quality of life after 12 months is significantly better than before implantation.

02

Conditions studied

  • Cystocele
  • Uterine Prolapse

Keywords

  • polypropylene mesh
  • prolapse
  • cystocele
  • surgical mesh
03

In context

Cystocele

71 studies on the registry are indexed under Cystocele; 5 are open to participants now.

This study's enrollment of 54 is below the median of 75 across 46 interventional studies indexed under Cystocele.

Browse Cystocele studies →

Lead sponsor

pfm medical gmbh is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Existence of a cystocele. Women with a symptomatic genital descensus: at least stage II (ICS-classification according POP-Q system). This applies to primary as well as recurrent intervention.
  2. Patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation.
  3. Patient information has been handed out and written consent is at hand.
  4. Patient has attained full age (18 years or older).

Exclusion criteria

Exclusion Criteria:

  1. Unfinished family planning, pregnancy or breast-feeding mother.
  2. Known intolerance to the mesh-implants under investigation.
  3. Lack of written patients' .
  4. Lack of patient compliance regarding data collection, treatment or follow-up investigations in the scope of the protocol.
  5. Patients with acute (within the last 12 months) carcinoma in the pelvic area.
  6. Patients with history of radiotherapy in the pelvic area.
  7. Patients with implanted anterior pelvic floor mesh.
  8. Patient is institutionalized by court or official order (MPG §20.3).
  9. Participation in another interventional clinical investigation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Other
    surgical mesh implantation

    Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.

    Device: TiLOOP® PRO Plus A

Interventions

  • DeviceTiLOOP® PRO Plus A

    The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.

06

What researchers measure

Primary outcomes

  1. Patient's Quality of Life

    By means of a validated questionnaire it will be shown whether the subjective quality of life after 12 months is significantly better than before implantation.

    Time frame: 12 months

Secondary outcomes

  1. Patient's Quality of Life

    The evaluation of changes in quality of life assessed by the P-QoL 6 months after implantation of the TiLOOP® PRO A surgical mesh compared to before implantation.

    Time frame: 6 months

  2. Adverse Events (AE)

    Assessment and analysis of all \[serious\] adverse events (\[S\]AEs) during the first 12 months after implantation along with a contextual placement of safety data based on current literature.

    Time frame: 6 weeks, 6 and 12 months

  3. Feasibility Check of Mesh implantation

    To evaluate mesh implantation, information about the duration of the procedure (minutes from cut to stitches) and the operability of the application set (easy, suitable, difficult, no set used) will be collected during the surgery. Taking together, this information will encapsulate the feasibility of the mesh implantation descriptively.

    Time frame: 1 day

  4. Number of complications and concomitant procedures

    Counting the number of intraoperative complications (e. g. lesion of the bladder, the urethra or the intestines) and concomitant procedures (e. g. hysterectomy, colporrhaphy, vaginal sacrospinal fixation) procedure-related adverse events as assessed by CTCAE v4.0 and common concomitant procedures will be evaluated.

    Time frame: 1 day

07

Study locations

5 sites
  • Klinik Tettnang GmbH
    Tettnang, Baden-Württemberg 88069, Germany
  • Klinikum Augsburg
    Augsburg, Bayern 86156, Germany
  • Klinikum Dresden-Friedrichstadt
    Dresden, Sachsen 01067, Germany
  • Klinikum Oberlausitzer Bergland gemeinnützige GmbH
    Zittau, Sachsen 02763, Germany
  • Ev. Amalie-Sieveking-Krankenhaus
    Hamburg, 22359, Germany
08

References and documents

Publications

  • Cadenbach-Blome T, Grebe M, Mengel M, Pauli F, Greser A, Funfgeld C. Significant Improvement in Quality of Life, Positive Effect on Sexuality, Lasting Reconstructive Result and Low Rate of Complications Following Cystocele Correction Using a Lightweight, Large-Pore, Titanised Polypropylene Mesh: Final Results of a National, Multicentre Observational Study. Geburtshilfe Frauenheilkd. 2019 Sep;79(9):959-968. doi: 10.1055/a-0984-6614. Epub 2019 Sep 11. PubMed 31523096 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Jul 2017, 17 months.

Of 19 interventional studies with no phase under Cystocele, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 76. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Feb 24, 2016
StartActual
Feb 1, 2016
Primary completionActual
Jul 31, 2017
CompletionActual
Jul 31, 2017
Last update
Oct 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02690220
Lead sponsor
pfm medical gmbh
Collaborators
Crolll Gmbh, Bayes GmbH, Aix Scientifics
Responsible party
Sponsor
First posted
Feb 24, 2016
Start date
Feb 1, 2016
Primary completion
Jul 31, 2017
Completion
Jul 31, 2017
Last update
Oct 23, 2019

Study contacts

Christian Fünfgeld, Dr. med.
principal investigator · Klinik Tettnang GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion